1. Scrip

Shire CEO: Mydayis To Be Big ADHD Drug, But No Ex-US Launch Planned (Yet)

 
• By Sten Stovall

Flemming Ornskov says FDA approval of long-lasting ADHD therapy Mydayis is part of Shire's plan to dramatically increase neuroscience revenues – but it won't launch the drug outside the US for some time.

ADHD
Shire CEO says resurrection of SHP465 part of plan to boost neuroscience revenues • Source: Shutterstock

FDA approval this week of Shire PLC's new, long-lasting ADHD drug Mydayis (SHP465) was long in the making - but the group sees it quickly becoming a major product for treating attention deficit hyperactivity disorder in the US and boosting its neuroscience franchise, CEO Flemming Ornskov told Scrip.

The Danish executive was speaking after the FDA June 20 approved the once-daily treatment, comprising three different types of drug-releasing beads, for patients 13 years and older with ADHD

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.